Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 10/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 10/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 10/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 10/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 10/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 10/20 | 0.49 |
| ▸ | PRCP | P42785 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14612068 | 0.82 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14019409 | 0.79 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14019433 | 0.79 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14044940 | 0.75 | OPRM1 (0.34) | — | |
| SCHEMBL14544032 | 0.71 | DRD2 (0.39) | — | |
| SCHEMBL14044943 | 0.69 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14079229 | 0.69 | PSEN1 (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL11965522 | 0.68 | PSEN1 (0.84) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14578293 | 0.68 | PSEN1 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14079228 | 0.66 | PSEN1 (0.79) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435748-B2 | Gamma-secretase inhibitors | MERCK SHARP & DOHME LTD. (GB) | 2008-10-14 | — | — | US | disclosed |
| US-20070088063-A1 | Gamma-secretase inhibitors | CASTRO PINEIRO JOSE L | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088063-A1 | Gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 7/4885APH1B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.